Source: Eur Respir Rev 2007; 16: 50-55
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Lode H.. Combination versus monotherapy for nosocomial pneumonia. Eur Respir Rev 2007; 16: 50-55

Member's Comments

No comment yet.

Related content which might interest you: Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Appropriateness and delay to initiate therapy in ventilator-associated pneumonia Source: Eur Respir J 2006; 27: 158-164 Year: 2006 Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia Source: Eur Respir J 2004; 24 : 644-648 Year: 2004 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP) Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008 The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis Source: Eur Respir J 2007; 30: 525-531 Year: 2007 Survival benefit of beta-lactam plus macrolide combined therapy versus beta-lactam plus quinolones in hospitalized community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: update on prognostic factors and therapeutic strategies Year: 2016 Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis Source: Eur Respir J 2012; 39: 611-618 Year: 2012 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Aerosolised treatment for VAP Source: Eur Respir Mon 2011; 53: 54-65 Year: 2011 Cost-effective antibiotic management of community acquired pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198 Year: 2004 The use of piperacillin/tazobactam for treatment of pneumonia in neutropenic patients Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 Intravenous steroids in the treatment of community-acquired pneumonia (CAP) Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004